Here we list the publications that the group has written or contributed to.

1 Accepted or published

  • Lawrence, R., Degtyarev, E., Griffiths, P., Trask, P., Lau, H., D’Alessio, D., Griebsch, I., Wallenstein, G., Cocks, K., Rufibach, K. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials (2020). Journal of Patient-Reported Outcomes, 4(1), 68. doi.
  • Degtyarev, E., Rufibach, K., Shentu, Y., Yung, G., Casey, M., Englert, S., Liu, F., Liu, Y., Sailer, O., Siegel, J., Sun, S., Tang, R., Zhou, J. Assessing the impact of COVID-19 on the objective and analysis of oncology clinical trials – application of the estimand framework (2020). Statistics in Biopharmaceutical Research, 12(4), 427-437. doi | arxiv.
  • Casey M., Degtyarev E., Lechuga M.J., Aimone P., Ravaud A., Motzer R., Liu F., Stalbovskaya V., Tang R., Butler E., Sailer O., Halabi S., George D. Estimand framework: Are we asking the right question? A case study in the solid tumor setting (2020). Pharmaceutical Statistics, 20, 324–334. doi.
  • Sun, S., Weber, J., Butler, E., Rufibach, K., Roychoudhury, S. Estimands in Hematology Trials (2021). Pharmaceutical Statistics, 20, 793-805. doi | arxiv. This paper was the 3rd most downloaded paper that appeared in 2021 in Pharmaceutical Statistics.
  • Bornkamp, B., Rufibach, K., Lin, J., Liu, Y., Mehrotra, D., Roychoudhury, S., Schmidli, H., Shentu, Y., Wolbers, M. Principal Stratum Strategy: Potential Role in Drug Development (2021). Pharmaceutical Statistics, 20, 737-751. doi | arxiv | github | markdown | This paper was the 4th most downloaded paper that appeared in 2021 in Pharmaceutical Statistics.
  • Manitz, J., Kan-Dobrosky, N., Buchner, H., Casadebaig, M.L., Degtyarev, E., Dey, J., Haddad, V., Fei, J., Martin, E., Mo, M., Rufibach, K., Shentu, Y., Stalbovskaya, V., Tang, R., Yung, G., Zhu, J. Estimands for Overall Survival in Clinical Trials with Treatment Switching in Oncology (2022). Pharmaceutical Statistics, 21, 150-162. doi.
  • Hampson, L.V., Degtyarev, E., Tang, R., Lin, J., Rufibach, K., Zheng, C. Comment on Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment (2021). Statistics in Biopharmaceutical Research, to appear. doi.

2 Submitted

  • Siegel, J.M., Grinsted, L., Liu, F., Weber, J., Englert, S., Casey, M. Censoring and censoring mechanisms in oncology in light of the estimands framework (2022). Submitted. | arxiv.
  • Siegel, J.M. Weber, J., Englert, S. The Role of Occlusion: Potential Extension of the ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis for Time-to-Event Oncology Studies (2022). Submitted. | arxiv.
  • Rufibach, K., Grinsted, L., Li, J., Weber, H.J., Zheng, C., and Zhou, J. Quantification of Follow-up Time in Oncology Clinical Trials with a Time-to-Event Endpoint: Asking the Right Questions. (2022). Submitted. | arXiv | github | markdown.
  • Liu, Y., Yang, M., Kil, S., Li, J., Mondal, S., Shentu, Y., Tian, H., Wang, L., Yung, G. From logic-respecting efficacy estimands to logic-ensuring analysis principle for time-to-event endpoint in randomized clinical trials with subgroups. (2022). Submitted.